Mark D. Eisner
- Pulmonary and Respiratory Medicine top 0.05%
- Chronic Obstructive Pulmonary Disease (COPD) Research 50
- Respiratory Support and Mechanisms 38
- Respiratory and Cough-Related Research 14
- Physiology top 0.2%
- Asthma and respiratory diseases 52
- Smoking Behavior and Cessation 20
- Immunology and Allergy top 0.5%
- Health, Toxicology and Mutagenesis top 0.5%
- Air Quality and Health Impacts 31
-
- Sepsis Diagnosis and Treatment 17
-
- Occupational exposure and asthma 11
- Co-authors
- Paul D. BlancMichael A. MatthayPatricia KatzEdward H. YelinCarlos IribarrenBruce ThompsonJohn R. BalmesPolly E. Parsons
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Mark D. Eisner
177 papers receiving 13.8k citations
Hit Papers
Peers
Comparison fields: 5 of 167
- Pulmonary and Respiratory Medicine 8.6k
- Physiology 5.4k
- Critical Care and Intensive Care Medicine 1.0k
- Immunology and Allergy 1.1k
- Health, Toxicology and Mutagenesis 1.9k
Countries citing papers authored by Mark D. Eisner
This map shows the geographic impact of Mark D. Eisner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. Eisner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. Eisner more than expected).
Fields of papers citing papers by Mark D. Eisner
This network shows the impact of papers produced by Mark D. Eisner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. Eisner. The network helps show where Mark D. Eisner may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark D. Eisner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 5 | |
| 2 | 2024 | 3 | |
| 3 | Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trialsbreakdown → | 2016 | 350 |
| 4 | 2015 | 74 | |
| 5 | 2011 | 110 | |
| 6 | 2010 | 48 | |
| 7 | An Official American Thoracic Society Public Policy Statement: Novel Risk Factors and the Global Burden of Chronic Obstructive Pulmonary Diseasebreakdown → | 2010 | 679 |
| 8 | 2009 | 42 | |
| 9 | 2008 | 129 | |
| 10 | 2008 | 146 | |
| 11 | 2008 | 114 | |
| 12 | 2007 | 122 | |
| 13 | 2006 | 51 | |
| 14 | 2005 | 54 | |
| 15 | 2004 | 199 | |
| 16 | 2002 | 100 | |
| 17 | 2002 | 83 | |
| 18 | 2001 | 152 | |
| 19 | 2001 | 199 | |
| 20 | 2000 | 40 |
About Mark D. Eisner
Mark D. Eisner is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Health, Toxicology and Mutagenesis, having authored 179 papers that have together received 14.3k indexed citations. Recurring topics across this work include Asthma and respiratory diseases (52 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (50 papers), Respiratory Support and Mechanisms (38 papers), Air Quality and Health Impacts (31 papers), Smoking Behavior and Cessation (20 papers), Sepsis Diagnosis and Treatment (17 papers), Respiratory and Cough-Related Research (14 papers) and Occupational exposure and asthma (11 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (8.6k citations), Physiology (5.4k citations) and Critical Care and Intensive Care Medicine (1.0k citations). Mark D. Eisner has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Paul D. Blanc, Michael A. Matthay, Patricia Katz, Edward H. Yelin, Carlos Iribarren, Bruce Thompson, John R. Balmes, Polly E. Parsons, Laura Trupin and Lorraine B. Ware. Their work appears in journals such as CHEST Journal, Critical Care Medicine, Thorax, American Journal of Respiratory and Critical Care Medicine and Journal of Allergy and Clinical Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.